Cadila Healthcare gets EIR from USFDA for Baddi facility
New Delhi: Drug firm Cadila Healthcare on Thursday said its Baddi facility in Himachal Pradesh has received establishment inspection report (EIR) from the US health regulator. "The company's formulations manufacturing facility located at Baddi, India, has received an EIR. The United States Food and Drug Administration (USFDA) had conducted an inspection at the facility from July 15 to 19, 2019," Cadila Healthcare said in a filing to BSE.
The EIR report stated that the classification of the facility is 'No Action Indicated (NAI)', it added.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here